OBJECTIVES: Genital ulcer disease (GUD) is associated with increased HIV-1-RNA shedding in antiretroviral therapy (ART)-naive women. The effect of GUD on HIV-1 shedding among ART-treated women is not known. The objective of this study was to test the hypothesis that genital ulcerations increase genital HIV-1-RNA shedding in women receiving ART. METHODS: Eligible women initiated ART and attended monthly visits with inspection for genital lesions and collection of genital swabs. GUD cases diagnosed after 2 months or more on ART were included for analysis and served as their own controls. HIV-1 RNA was quantitated in specimens collected before, during and after GUD for all cases. The lower limit of quantitation was 100 HIV-1-RNA copies/swab. Using the pre-GUD visit as the reference, the detection of genital HIV-1 RNA before versus during and after GUD episodes was compared. RESULTS: 36 women had GUD episodes after ART initiation. HIV-1 RNA was detected before, during and after GUD in cervical secretions from four (11%), one (3%) and six (17%) women, respectively, and in vaginal secretions from three (8%), four (11%) and four (11%) women, respectively. After adjustment for time on ART, there was no difference in the detection of cervical HIV-1 RNA before versus during GUD (adjusted OR 0.22, 95% CI 0.04 to 1.23). Likewise, GUD did not increase HIV-1 detection in vaginal secretions (adjusted OR 1.32, 95% CI 0.29 to 5.92). CONCLUSIONS: GUD did not significantly increase cervical or vaginal HIV-1 shedding. The results suggest that ART maintains its effectiveness for genital HIV-1 suppression despite GUD episodes.
OBJECTIVES:Genital ulcer disease (GUD) is associated with increased HIV-1-RNA shedding in antiretroviral therapy (ART)-naive women. The effect of GUD on HIV-1 shedding among ART-treated women is not known. The objective of this study was to test the hypothesis that genital ulcerations increase genital HIV-1-RNA shedding in women receiving ART. METHODS: Eligible women initiated ART and attended monthly visits with inspection for genital lesions and collection of genital swabs. GUD cases diagnosed after 2 months or more on ART were included for analysis and served as their own controls. HIV-1 RNA was quantitated in specimens collected before, during and after GUD for all cases. The lower limit of quantitation was 100 HIV-1-RNA copies/swab. Using the pre-GUD visit as the reference, the detection of genital HIV-1 RNA before versus during and after GUD episodes was compared. RESULTS: 36 women had GUD episodes after ART initiation. HIV-1 RNA was detected before, during and after GUD in cervical secretions from four (11%), one (3%) and six (17%) women, respectively, and in vaginal secretions from three (8%), four (11%) and four (11%) women, respectively. After adjustment for time on ART, there was no difference in the detection of cervical HIV-1 RNA before versus during GUD (adjusted OR 0.22, 95% CI 0.04 to 1.23). Likewise, GUD did not increase HIV-1 detection in vaginal secretions (adjusted OR 1.32, 95% CI 0.29 to 5.92). CONCLUSIONS: GUD did not significantly increase cervical or vaginal HIV-1 shedding. The results suggest that ART maintains its effectiveness for genital HIV-1 suppression despite GUD episodes.
Authors: Susan M Graham; Sarah E Holte; Norbert M Peshu; Barbra A Richardson; Dana D Panteleeff; Walter G Jaoko; Jeckoniah O Ndinya-Achola; Kishorchandra N Mandaliya; Julie M Overbaugh; R Scott McClelland Journal: AIDS Date: 2007-02-19 Impact factor: 4.177
Authors: J M Pickering; J A G Whitworth; P Hughes; M Kasse; D Morgan; B Mayanja; L Van der Paal; P Mayaud Journal: Sex Transm Infect Date: 2005-12 Impact factor: 3.519
Authors: Niloufar Ameli; Peter Bacchetti; Rhoda Ashley Morrow; Nancy A Hessol; Timothy Wilkin; Mary Young; Mardge Cohen; Howard Minkoff; Stephen J Gange; Ruth M Greenblatt Journal: AIDS Date: 2006-04-24 Impact factor: 4.177
Authors: N Nagot; A Ouedraogo; I Konate; H A Weiss; V Foulongne; M C Defer; A Sanon; P Becquart; M Segondy; A Sawadogo; P Van de Perre; P Mayaud Journal: J Infect Dis Date: 2008-07-15 Impact factor: 5.226
Authors: P Mayaud; N Nagot; I Konaté; A Ouedraogo; H A Weiss; V Foulongne; M-C Defer; A Sawadogo; M Segondy; P Van de Perre Journal: Sex Transm Infect Date: 2008-07-02 Impact factor: 3.519
Authors: Sarah Benki; Sara B Mostad; Barbra A Richardson; Kishorchandra Mandaliya; Joan K Kreiss; Julie Overbaugh Journal: J Infect Dis Date: 2004-05-24 Impact factor: 5.226
Authors: T R Suntoke; A Hardick; A A R Tobian; B Mpoza; O Laeyendecker; D Serwadda; P Opendi; C A Gaydos; R H Gray; M J Wawer; T C Quinn; S J Reynolds Journal: Sex Transm Infect Date: 2008-12-09 Impact factor: 3.519
Authors: Abdoulaye Ouedraogo; Nicolas Nagot; Laurence Vergne; Issouf Konate; Helen A Weiss; Marie-Christine Defer; Vincent Foulongne; Anselme Sanon; Jean-Baptiste Andonaba; Michel Segondy; Philippe Mayaud; Philippe Van de Perre Journal: AIDS Date: 2006-11-28 Impact factor: 4.177
Authors: Caroline Mitchell; Jennifer E Balkus; Jennifer McKernan-Mullin; Susan E Cohn; Amneris E Luque; Christina Mwachari; Craig R Cohen; Robert Coombs; Lisa M Frenkel; Jane Hitti Journal: J Acquir Immune Defic Syndr Date: 2013-02-01 Impact factor: 3.731
Authors: Linnet N Masese; Susan M Graham; Ruth Gitau; Nobert Peshu; Walter Jaoko; Jeckoniah O Ndinya-Achola; Kishorchandra Mandaliya; Barbra A Richardson; Julie Overbaugh; R Scott McClelland Journal: BMC Infect Dis Date: 2011-11-03 Impact factor: 3.090
Authors: Norbert Donhauser; Kathrin Pritschet; Martin Helm; Thomas Harrer; Philipp Schuster; Moritz Ries; Georg Bischof; Jörg Vollmer; Sigrun Smola; Barbara Schmidt Journal: PLoS One Date: 2012-03-21 Impact factor: 3.240
Authors: David Champredon; Steven E Bellan; Wim Delva; Spencer Hunt; Chyun-Fung Shi; Marek Smieja; Jonathan Dushoff Journal: BMC Infect Dis Date: 2015-06-30 Impact factor: 3.090